ClinicalTrials.gg
CompletedNCT00195650Updated Aug 31, 2012Results posted

Long Term Open Label Continuation Study

A Phase 3 interventional study of Adalimumab in Rheumatoid Arthritis, sponsored by Abbott. Completed at 92 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-08-31.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
846
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.

Enrollment
8th of 87
846 · median 160
Started
2000
with 3 others
Phase 3
36 of 87
1 open now
Registered
2nd of 87
by date
Lead sponsor
22 of 87
Abbott

Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 8th largest by enrollment, is one of 4 that started in 2000, is one of 36 in phase 3, and was the 2nd registered.

Arthritis, Rheumatoid

3,336 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing adalimumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of the study was to assess the long-term safety and clinical efficacy following repeated administration of adalimumab in patients with rheumatoid arthritis.

Read the detailed description

Study DE020 was a multicenter, open-label continuation study for patients with rheumatoid arthritis who had participated in a prior Phase 1, 2, or 3 adalimumab study in the United States or Canada, had a favorable safety and efficacy profile when treated with adalimumab, and met the eligibility criteria for the continuation study. Participants received subcutaneous injections of adalimumab every other week (eow) or monthly based on the adalimumab regimen received in the prior study (i.e., participants who received monthly dosing in the prior study began the continuation study on monthly dosing; all other participants began adalimumab dosing at eow intervals). Participants who maintained an American College of Rheumatology 50% (ACR50) response for 2 consecutive visits could have their dosing interval lengthened to a monthly dosing schedule. Safety and efficacy data were collected over 520 weeks (10 years). Both safety and efficacy data were analyzed using all participants who received at least 1 dose of open-label adalimumab in the 10-year continuation study DE020 (the Full Analysis Set, n=846). Three patients who entered the continuation study but were never dosed were excluded from all analyses.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant was in a prior D2E7 (adalimumab) study
  • Participant was age 18 or older and in good health (Investigator discretion) with a recent stable medical history.

Exclusion criteria

Exclusion Criteria

  • Participant was considered by the investigator, for any reason, to be an unsuitable candidate for the study
  • Participant was a female subject who is pregnant or breast-feeding or considering becoming pregnant
  • Participant had any ongoing chronic or active infection
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
846 participants (actual)

Study arms

  • Experimental
    Adalimumab

    Open-label adalimumab 40 mg

    Biological: Adalimumab

Interventions

  • BiologicalAdalimumab

    Subcutaneous injection of 40 mg adalimumab every other week (eow) or monthly for up to 520 weeks (10 years)

    Also known as: Humira, ABT-D2E7

06

What researchers measure

Primary outcomes

  1. Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 520

    ACR20 response criteria were: \>=20% improvement in tender joint count; \>=20% improvement in swollen joint count; and \>=20% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.

    Time frame: Week 520

  2. Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 260

    ACR20 response criteria were: \>=20% improvement in tender joint count; \>=20% improvement in swollen joint count; and \>=20% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.

    Time frame: Week 260

  3. Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 520

    ACR50 response criteria were: \>=50% improvement in tender joint count; \>=50% improvement in swollen joint count; and \>=50% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.

    Time frame: Week 520

  4. Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 260

    ACR50 response criteria were: \>=50% improvement in tender joint count; \>=50% improvement in swollen joint count; and \>=50% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.

    Time frame: Week 260

  5. Number of Participants Meeting American College of Rheumatology 70% (ACR70) Response Criteria at Week 520

    ACR70 response criteria were: \>=70% improvement in tender joint count; \>=70% improvement in swollen joint count; and \>=70% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.

    Time frame: Week 520

  6. Number of Participants Meeting American College of Rheumatology 70% (ACR70) Response Criteria at Week 260

    ACR70 response criteria were: \>=70% improvement in tender joint count; \>=70% improvement in swollen joint count; and \>=70% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.

    Time frame: Week 260

  7. Number of Participants in Clinical Remission (Based on Modified Disease Activity Score) at Week 520

    Clinical remission on modified Disease Activity Score (DAS28) was a value \<2.6; \>=2.6 to \<=3.2 indicated low disease activity; \>3.2 to \<=5.1 indicated moderate disease activity; and \>5.1 indicated high disease activity. DAS28 score is calculated using the number of tender joints and swollen joints (out of 28 each), patient global assessment of disease activity, and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response).

    Time frame: Week 520

  8. Number of Participants in Clinical Remission (Based on Modified Disease Activity Score) at Week 260

    Clinical remission on modified Disease Activity Score (DAS28) was a value \<2.6; \>=2.6 to \<=3.2 indicated low disease activity; \>3.2 to \<=5.1 indicated moderate disease activity; and \>5.1 indicated high disease activity. DAS28 score is calculated using the number of tender joints and swollen joints (out of 28 each), patient global assessment of disease activity, and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response).

    Time frame: Week 260

  9. Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 520

    The HAQ-DI is a measure of disability that ranges from 0 to 3. Decrease in score indicates improvement in physical function; a decrease of 0.22 or greater from Baseline score is clinically significant. Participants assessed their ability to perform at least 6 of the following 8 specific tasks (1. dress/groom; 2. arise; 3. eat; 4. walk; 5. reach; 6. grip; 7. maintain hygiene; 8. maintain daily activity) over the past week by marking their response on a questionnaire. Possible responses/scores included the following: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). The 8 task scores are added and the sum is divided by the number of tasks assessed (range = 6 to 8). This yields a HAQ-DI score of 0 to 3.

    Time frame: Baseline of prior Phase 1, 2, or 3 adalimumab study and Week 520

  10. Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 260

    The HAQ-DI is a measure of disability that ranges from 0 to 3. Decrease in score indicates improvement in physical function; a decrease of 0.22 or greater from Baseline score is clinically significant. Participants assessed their ability to perform at least 6 of the following 8 specific tasks (1. dress/groom; 2. arise; 3. eat; 4. walk; 5. reach; 6. grip; 7. maintain hygiene; 8. maintain daily activity) over the past week by marking their response on a questionnaire. Possible responses/scores included the following: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). The 8 task scores are added and the sum is divided by the number of tasks assessed (range = 6 to 8). This yields a HAQ-DI score of 0 to 3.

    Time frame: Baseline of prior Phase 1, 2, or 3 adalimumab study and Week 260

Secondary outcomes

  1. Reported Adverse Events

    Adverse events were collected during the course of the study (after the first adalimumab injection in this continuation study DE020 through 70 days after the last adalimumab injection) for all participants who received at least 1 dose of open-label adalimumab in the continuation study (Full Analysis Set). The number of participants experiencing any adverse event (serious and non-serious) are summarized. See the Reported Adverse Events section for details.

    Time frame: Duration of study (up to 520 weeks [10 years])

07

Results

Posted Jul 31, 2012

Participant flow

Participant flow — Overall Study
MilestoneAdalimumab
Started846
Completed321
Not completed525
Withdrew: Adverse event194
Withdrew: Lack of efficacy99
Withdrew: Withdrawal by subject67
Withdrew: Lost to follow-up44
Withdrew: Death23
Withdrew: Protocol violation15
Withdrew: Administrative reasons83

Outcome measures

PrimaryNumber of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 520

ACR20 response criteria were: \>=20% improvement in tender joint count; \>=20% improvement in swollen joint count; and \>=20% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.

Time frame:
Week 520
Reported as:
Number · participants
Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 520
participantsAdalimumab
Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 520187
PrimaryNumber of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 260

ACR20 response criteria were: \>=20% improvement in tender joint count; \>=20% improvement in swollen joint count; and \>=20% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.

Time frame:
Week 260
Reported as:
Number · participants
Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 260
participantsAdalimumab
Number of Participants Meeting American College of Rheumatology 20% (ACR20) Response Criteria at Week 260402
PrimaryNumber of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 520

ACR50 response criteria were: \>=50% improvement in tender joint count; \>=50% improvement in swollen joint count; and \>=50% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.

Time frame:
Week 520
Reported as:
Number · participants
Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 520
participantsAdalimumab
Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 520132
SecondaryReported Adverse Events

Adverse events were collected during the course of the study (after the first adalimumab injection in this continuation study DE020 through 70 days after the last adalimumab injection) for all participants who received at least 1 dose of open-label adalimumab in the continuation study (Full Analysis Set). The number of participants experiencing any adverse event (serious and non-serious) are summarized. See the Reported Adverse Events section for details.

Time frame:
Duration of study (up to 520 weeks [10 years])
Reported as:
Number · participants
Reported Adverse Events
participantsAdalimumab
Reported Adverse Events808
PrimaryNumber of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 260

ACR50 response criteria were: \>=50% improvement in tender joint count; \>=50% improvement in swollen joint count; and \>=50% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.

Time frame:
Week 260
Reported as:
Number · participants
Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 260
participantsAdalimumab
Number of Participants Meeting American College of Rheumatology 50% (ACR50) Response Criteria at Week 260279
PrimaryNumber of Participants Meeting American College of Rheumatology 70% (ACR70) Response Criteria at Week 520

ACR70 response criteria were: \>=70% improvement in tender joint count; \>=70% improvement in swollen joint count; and \>=70% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.

Time frame:
Week 520
Reported as:
Number · participants
Number of Participants Meeting American College of Rheumatology 70% (ACR70) Response Criteria at Week 520
participantsAdalimumab
Number of Participants Meeting American College of Rheumatology 70% (ACR70) Response Criteria at Week 52078
PrimaryNumber of Participants Meeting American College of Rheumatology 70% (ACR70) Response Criteria at Week 260

ACR70 response criteria were: \>=70% improvement in tender joint count; \>=70% improvement in swollen joint count; and \>=70% improvement in at least 3 of the 5 remaining ACR core measures: patient assessment of pain; patient global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \[HAQ\]); and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response). All improvements were assessed relative to the baseline of the prior study.

Time frame:
Week 260
Reported as:
Number · participants
Number of Participants Meeting American College of Rheumatology 70% (ACR70) Response Criteria at Week 260
participantsAdalimumab
Number of Participants Meeting American College of Rheumatology 70% (ACR70) Response Criteria at Week 260179
PrimaryNumber of Participants in Clinical Remission (Based on Modified Disease Activity Score) at Week 520

Clinical remission on modified Disease Activity Score (DAS28) was a value \<2.6; \>=2.6 to \<=3.2 indicated low disease activity; \>3.2 to \<=5.1 indicated moderate disease activity; and \>5.1 indicated high disease activity. DAS28 score is calculated using the number of tender joints and swollen joints (out of 28 each), patient global assessment of disease activity, and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response).

Time frame:
Week 520
Reported as:
Number · participants
Number of Participants in Clinical Remission (Based on Modified Disease Activity Score) at Week 520
participantsAdalimumab
Number of Participants in Clinical Remission (Based on Modified Disease Activity Score) at Week 520135
PrimaryNumber of Participants in Clinical Remission (Based on Modified Disease Activity Score) at Week 260

Clinical remission on modified Disease Activity Score (DAS28) was a value \<2.6; \>=2.6 to \<=3.2 indicated low disease activity; \>3.2 to \<=5.1 indicated moderate disease activity; and \>5.1 indicated high disease activity. DAS28 score is calculated using the number of tender joints and swollen joints (out of 28 each), patient global assessment of disease activity, and C-reactive protein (a laboratory marker of inflammation that is sensitive to acute changes in inflammatory response).

Time frame:
Week 260
Reported as:
Number · participants
Number of Participants in Clinical Remission (Based on Modified Disease Activity Score) at Week 260
participantsAdalimumab
Number of Participants in Clinical Remission (Based on Modified Disease Activity Score) at Week 260243
PrimaryChange From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 520

The HAQ-DI is a measure of disability that ranges from 0 to 3. Decrease in score indicates improvement in physical function; a decrease of 0.22 or greater from Baseline score is clinically significant. Participants assessed their ability to perform at least 6 of the following 8 specific tasks (1. dress/groom; 2. arise; 3. eat; 4. walk; 5. reach; 6. grip; 7. maintain hygiene; 8. maintain daily activity) over the past week by marking their response on a questionnaire. Possible responses/scores included the following: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). The 8 task scores are added and the sum is divided by the number of tasks assessed (range = 6 to 8). This yields a HAQ-DI score of 0 to 3.

Time frame:
Baseline of prior Phase 1, 2, or 3 adalimumab study and Week 520
Reported as:
Mean · units on a scale
Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 520
units on a scaleAdalimumab
Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 520-0.52 ± 0.662
PrimaryChange From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 260

The HAQ-DI is a measure of disability that ranges from 0 to 3. Decrease in score indicates improvement in physical function; a decrease of 0.22 or greater from Baseline score is clinically significant. Participants assessed their ability to perform at least 6 of the following 8 specific tasks (1. dress/groom; 2. arise; 3. eat; 4. walk; 5. reach; 6. grip; 7. maintain hygiene; 8. maintain daily activity) over the past week by marking their response on a questionnaire. Possible responses/scores included the following: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). The 8 task scores are added and the sum is divided by the number of tasks assessed (range = 6 to 8). This yields a HAQ-DI score of 0 to 3.

Time frame:
Baseline of prior Phase 1, 2, or 3 adalimumab study and Week 260
Reported as:
Mean · units on a scale
Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 260
units on a scaleAdalimumab
Change From Baseline in the Disability Index of the Health Assessment Questionnaire (HAQ) at Week 260-0.59 ± 0.628

Adverse events

Collected over After the first adalimumab injection in this continuation study DE020 to 70 days after the last adalimumab injection.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab—432/846 (51.1%)768/846 (90.8%)
Most frequent serious events
Showing 10 of 373
Most frequent serious events
EventAdalimumab
Rheumatoid arthritisMusculoskeletal and connective tissue disorders73/846
OsteoarthritisMusculoskeletal and connective tissue disorders44/846
PneumoniaInfections and infestations36/846
CellulitisInfections and infestations20/846
Angina pectorisCardiac disorders14/846
ArthralgiaMusculoskeletal and connective tissue disorders11/846
Coronary artery diseaseCardiac disorders10/846
Myocardial infarctionCardiac disorders10/846
Atrial fibrillationCardiac disorders9/846
Cerebrovascular accidentNervous system disorders9/846
Most frequent other events
Showing 10 of 59
Most frequent other events
EventAdalimumab
Upper respiratory tract infectionInfections and infestations392/846
Rheumatoid arthritisMusculoskeletal and connective tissue disorders215/846
SinusitisInfections and infestations211/846
NasopharyngitisInfections and infestations193/846
BronchitisInfections and infestations179/846
HypertensionVascular disorders176/846
Urinary tract infectionInfections and infestations170/846
Back painMusculoskeletal and connective tissue disorders147/846
DiarrhoeaGastrointestinal disorders134/846
RashSkin and subcutaneous tissue disorders131/846

Baseline characteristics

Age Continuous
Age Continuous(years)Adalimumab
Mean55.6 ± 12.19
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab
Female661
Male185
08

Study locations

92 sites
  • Site Reference ID/Investigator# 538
    Birmingham, Alabama 35205, United States
  • Site Reference ID/Investigator# 4111
    Birmingham, Alabama 35294-7201, United States
  • Site Reference ID/Investigator# 4113
    Mobile, Alabama 36608, United States
  • Site Reference ID/Investigator# 408
    Anchorage, Alaska 99508, United States
  • Site Reference ID/Investigator# 537
    Tucson, Arizona 85710, United States
  • Site Reference ID/Investigator# 66822
    Anaheim, California 92801, United States
  • Site Reference ID/Investigator# 557
    La Jolla, California 92037-0943, United States
  • Site Reference ID/Investigator# 387
    Los Angeles, California 90048, United States
  • Site Reference ID/Investigator# 555
    Los Angeles, California 90095, United States
  • Site Reference ID/Investigator# 552
    Santa Barbara, California 93105, United States
  • Site Reference ID/Investigator# 66864
    Santa Monica, California 90404, United States
  • Site Reference ID/Investigator# 535
    Stanford, California 94305, United States
  • Site Reference ID/Investigator# 3412
    Upland, California 91786, United States
  • Site Reference ID/Investigator# 451
    Westlake Village, California 91361, United States
  • Site Reference ID/Investigator# 572
    Colorado Springs, Colorado 80910, United States
  • Site Reference ID/Investigator# 4109
    Denver, Colorado 80230, United States
  • Site Reference ID/Investigator# 541
    Danbury, Connecticut 06810, United States
  • Site Reference ID/Investigator# 654
    Milford, Connecticut 06460, United States
  • Site Reference ID/Investigator# 655
    Wilmington, Delaware 19808, United States
  • Site Reference ID/Investigator# 455
    Daytona Beach, Florida 32114, United States
  • Site Reference ID/Investigator# 431
    Fort Lauderdale, Florida 33334, United States
  • Site Reference ID/Investigator# 574
    Fort Myers, Florida 33901, United States
  • Site Reference ID/Investigator# 66843
    Gainesville, Florida 32605, United States
  • Site Reference ID/Investigator# 579
    Orlando, Florida 32804, United States
  • Site Reference ID/Investigator# 571
    Palm Harbor, Florida 34684, United States
  • Site Reference ID/Investigator# 651
    Sarasota, Florida 34239, United States
  • Site Reference ID/Investigator# 66863
    St. Petersburg, Florida 33710, United States
  • Site Reference ID/Investigator# 542
    Tampa, Florida 33609, United States
  • Site Reference ID/Investigator# 415
    Vero Beach, Florida 32962, United States
  • Site Reference ID/Investigator# 652
    Zephyrhills, Florida 33542, United States
  • Site Reference ID/Investigator# 449
    Boise, Idaho 83702, United States
  • Site Reference ID/Investigator# 4110
    Boise, Idaho 83706, United States
  • Site Reference ID/Investigator# 650
    Coeur D'Alene, Idaho 83814, United States
  • Site Reference ID/Investigator# 578
    Chicago, Illinois 60612, United States
  • Site Reference ID/Investigator# 4112
    Indianapolis, Indiana 46260, United States
  • Site Reference ID/Investigator# 547
    Louisville, Kentucky 40291, United States
  • Site Reference ID/Investigator# 534
    Metairie, Louisiana 70006, United States
  • Site Reference ID/Investigator# 544
    Chevy Chase, Maryland 20815, United States
  • Site Reference ID/Investigator# 653
    Boston, Massachusetts 02115, United States
  • Site Reference ID/Investigator# 4114
    Worcester, Massachusetts 01610, United States
  • Site Reference ID/Investigator# 546
    Petoskey, Michigan 49770, United States
  • Site Reference ID/Investigator# 577
    St. Louis, Missouri 63128, United States
  • Site Reference ID/Investigator# 549
    Billings, Montana 59101, United States
  • Site Reference ID/Investigator# 561
    Reno, Nevada 89502, United States
  • Site Reference ID/Investigator# 573
    Dover, New Jersey 07801, United States
  • Site Reference ID/Investigator# 66842
    Toms River, New Jersey 08755, United States
  • Site Reference ID/Investigator# 559
    Voorhees, New Jersey 08043, United States
  • Site Reference ID/Investigator# 562
    Albuquerque, New Mexico 87102, United States
  • Site Reference ID/Investigator# 66823
    Brooklyn, New York 11203, United States
  • Site Reference ID/Investigator# 432
    Lake Success, New York 11042, United States
  • Site Reference ID/Investigator# 657
    New York, New York 10003, United States
  • Site Reference ID/Investigator# 647
    New York, New York 10021, United States
  • Site Reference ID/Investigator# 545
    Port Jefferson Station, New York 11776, United States
  • Site Reference ID/Investigator# 540
    Syracuse, New York 13210, United States
  • Site Reference ID/Investigator# 646
    Statesville, North Carolina 28625, United States
  • Site Reference ID/Investigator# 438
    Cincinnati, Ohio 45219, United States
  • Site Reference ID/Investigator# 436
    Dayton, Ohio 45408, United States
  • Site Reference ID/Investigator# 548
    Bend, Oregon 97701, United States
  • Site Reference ID/Investigator# 553
    Eugene, Oregon 97401, United States
  • Site Reference ID/Investigator# 532
    Portland, Oregon 97205, United States
  • Site Reference ID/Investigator# 570
    Bethlehem, Pennsylvania 18015, United States
  • Site Reference ID/Investigator# 575
    Ridley Park, Pennsylvania 19078-2210, United States
  • Site Reference ID/Investigator# 585
    Willow Grove, Pennsylvania 19090, United States
  • Site Reference ID/Investigator# 2435
    Dallas, Texas 75231, United States
  • Site Reference ID/Investigator# 536
    Richmond, Virginia 23219, United States
  • Site Reference ID/Investigator# 649
    Everett, Washington 98201, United States
  • Site Reference ID/Investigator# 66862
    Everett, Washington 98201, United States
  • Site Reference ID/Investigator# 531
    Kirkland, Washington 98034, United States
  • Site Reference ID/Investigator# 412
    Olympia, Washington 98502, United States
  • Site Reference ID/Investigator# 658
    Spokane, Washington 99204, United States
  • Site Reference ID/Investigator# 576
    Vancouver, Washington 98664, United States
  • Site Reference ID/Investigator# 551
    Yakima, Washington 98902, United States
  • Site Reference ID/Investigator# 656
    Glendale, Wisconsin 53217, United States
  • Site Reference ID/Investigator# 539
    Milwaukee, Wisconsin 53215, United States
  • Site Reference ID/Investigator# 513
    Calgary, T2V 1P9, Canada
  • Site Reference ID/Investigator# 568
    Charlottetown, C1A 5Y8, Canada
  • Site Reference ID/Investigator# 565
    Hamilton, L8N 1Y2, Canada
  • Site Reference ID/Investigator# 564
    Hamilton, L8N 2B6, Canada
  • Site Reference ID/Investigator# 569
    Kitchener, N2M 5N6, Canada
  • Site Reference ID/Investigator# 3440
    Montreal, H2L 1S6, Canada
  • Site Reference ID/Investigator# 413
    Montreal, H3Z 2Z3, Canada
  • Site Reference ID/Investigator# 66805
    North York, M3H 5Y8, Canada
  • Site Reference ID/Investigator# 66807
    North York, M3H 5Y8, Canada
  • Site Reference ID/Investigator# 414
    Ottawa, K1H 7W9, Canada
  • Site Reference ID/Investigator# 566
    Pointe-Claire, H9J 3W3, Canada
  • Site Reference ID/Investigator# 2467
    Sainte-Foy, Quebec, G1W 4R4, Canada
  • Site Reference ID/Investigator# 66804
    Scarborough, M1B 4Y9, Canada
  • Site Reference ID/Investigator# 563
    St. John's, A1B 3E1, Canada
  • Site Reference ID/Investigator# 2466
    Toronto, M4N 3M5, Canada
  • Site Reference ID/Investigator# 567
    Toronto, M5L 3L9, Canada
  • Site Reference ID/Investigator# 3442
    Vancouver, V5Z 1L7, Canada
  • Site Reference ID/Investigator# 514
    Winnipeg, R3A 1M4, Canada
09

References and documents

Publications

  • Furst DE, Kavanaugh A, Florentinus S, Kupper H, Karunaratne M, Birbara CA. Final 10-year effectiveness and safety results from study DE020: adalimumab treatment in patients with rheumatoid arthritis and an inadequate response to standard therapy. Rheumatology (Oxford). 2015 Dec;54(12):2188-97. doi: 10.1093/rheumatology/kev249. Epub 2015 Jul 21. PubMed 26199453 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2000, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2012, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 20, 2005
Start
Jul 2000
Primary completionActual
May 2011
CompletionActual
May 2011
Results first posted
Jul 31, 2012
Last update
Aug 31, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 31, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00195650
Lead sponsor
Abbott
Responsible party
Sponsor
First posted
Sep 20, 2005
Start date
Jul 2000
Primary completion
May 2011
Completion
May 2011
Results posted
Jul 31, 2012
Last update
Aug 31, 2012

Study contacts

Hartmut Kupper, MD
study director · Abbott

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion